Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells

Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo

(2020) Li‐Na Zhang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells

(2020) Jingqiu Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

(2020) Zhuo-Xun Wu et al.   Cancers

Mechanisms of Multidrug Resistance in Cancer Chemotherapy

(2020) Karol Bukowski et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells

(2020) Zhuo-Xun Wu et al.   Frontiers in Oncology

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells

(2020) Zhuo‐Xun Wu et al.   CANCER SCIENCE

Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators

(2020) Bruno M. F. Gonçalves et al.   MOLECULES

Structural insight into substrate and inhibitor discrimination by human P-glycoprotein

(2019) Amer Alam et al.   SCIENCE

Modelling dose and schedule effects of AZD2811 nanoparticles targeting aurora kinase B for treatment of diffuse large B-cell lymphoma

(2019) Nicolas Floc'h et al.   MOLECULAR CANCER THERAPEUTICS

Synthesis and Evaluation of Dibenzothiophene Analogues as Pin1 Inhibitors for Cervical Cancer Therapy

(2019) Ke-Jia Wu et al.   ACS Omega

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells

(2019) Zhuo-Xun Wu et al.   BIOCHEMICAL PHARMACOLOGY

Reversible inhibition of efflux transporters by hydrogel microdevices

(2019) Elizabeth S. Levy et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines

(2018) Chung-Pu Wu et al.   BIOCHEMICAL PHARMACOLOGY

Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions

(2018) Rebecca R. Crawford et al.   DRUG METABOLISM AND DISPOSITION

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia

(2018) Raquel Maia et al.   MOLECULES

Structure and Function of Multidrug Resistance Protein 1

(2018) E. N. Yakusheva et al.   BIOCHEMISTRY-MOSCOW

Drug resistance in multiple myeloma

(2018) Pawel Robak et al.   CANCER TREATMENT REVIEWS

Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance

(2018) Ning Ji et al.   BIOCHEMICAL PHARMACOLOGY

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies

(2017) Ankit C. Borisa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies

(2017) Ricardo J. Ferreira et al.   Scientific Reports

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies

(2016) Wen Li et al.   DRUG RESISTANCE UPDATES

Structural and Pharmacological Studies of an ABC Multidrug Transporter

(2016) Tomohiro Yamaguchi   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines

(2016) Takaaki Oba et al.   Oncotarget

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

(2015) Manik Amin et al.   INVESTIGATIONAL NEW DRUGS

Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1

(2015) Chung-Pu Wu et al.   MOLECULAR PHARMACEUTICS

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

(2015) Gerald S. Falchook et al.   SEMINARS IN ONCOLOGY

Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

(2015) Joost C. M. Uitdehaag et al.   PLoS One

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

(2014) Antonino Maria Spartà et al.   CELL CYCLE

Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances

(2014) Evanthia Lionta et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

(2013) E Tavanti et al.   BRITISH JOURNAL OF CANCER

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

(2013) Serena Marchetti et al.   INVESTIGATIONAL NEW DRUGS

ABCB1 Structural Models, Molecular Docking, and Synthesis of New Oxadiazolothiazin-3-one Inhibitors

(2013) Camillo Rosano et al.   ACS Medicinal Chemistry Letters

Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202

(2012) Chao Cheng et al.   MOLECULAR PHARMACEUTICS

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

(2010) Nicholas D. Adams et al.   JOURNAL OF MEDICINAL CHEMISTRY

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

(2009) Oleg Trott et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS